Literature DB >> 10518303

Genetic aspects of hepatocellular carcinogenesis.

M Ozturk1.   

Abstract

Hepatocellular carcinoma (HCC) is linked etiologically to viruses (hepatitis B virus [HBV] and hepatitis C virus [HCV]), chemical carcinogens (i.e., aflatoxins), and other environmental and host factors causing chronic liver injury. Some hepatoblastomas may be linked to inherited gene mutations, but adult hereditary HCC appears to be rare. HCCs display gross genomic alterations, including DNA rearrangements associated with HBV DNA integration, loss of heterozygosity, and, less importantly, chromosomal amplifications and loss of imprinting. Many genes with somatic mutations have now been identified in these tumors. Most frequently involved genes are tumor suppressor genes such as p53, M6P/IGF2R, beta-catenin, p16INK4A, and retinoblastoma genes. Most identified mutations are somatic, but germline mutations of p16INK4A, APC, and BRCA2 have also been reported. Oncogenic activation of several cellular genes such as cyclin D and cyclin A have been described in HCC, but the possible implication of candidate viral oncogenes (i.e., X protein of HBV) is still debated. A comprehensive analysis of all the genetic changes described for HCC demonstrates that at least four different growth regulatory pathways are altered in these tumors. However, each pathway appears to be implicated in a limited fraction of these tumors, suggesting that HCCs are genetically heterogenous neoplasms. This genetic heterogeneity correlates with the heterogeneity of etiologic factors implicated in HCC.

Entities:  

Mesh:

Year:  1999        PMID: 10518303     DOI: 10.1055/s-2007-1007113

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  31 in total

1.  Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma.

Authors:  Gang Zeng; Matt Germinaro; Amanda Micsenyi; Navjot K Monga; Aaron Bell; Ajit Sood; Vanita Malhotra; Neena Sood; Vandana Midda; Dulabh K Monga; Demetrius M Kokkinakis; Satdarshan P S Monga
Journal:  Neoplasia       Date:  2006-04       Impact factor: 5.715

Review 2.  Hepatocellular carcinoma: therapy and prevention.

Authors:  Hubert E Blum
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

3.  The cyclin E regulator cullin 3 prevents mouse hepatic progenitor cells from becoming tumor-initiating cells.

Authors:  Uta Kossatz; Kai Breuhahn; Benita Wolf; Matthias Hardtke-Wolenski; Ludwig Wilkens; Doris Steinemann; Stephan Singer; Felicitas Brass; Stefan Kubicka; Brigitte Schlegelberger; Peter Schirmacher; Michael P Manns; Jeffrey D Singer; Nisar P Malek
Journal:  J Clin Invest       Date:  2010-10-11       Impact factor: 14.808

4.  Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma.

Authors:  Josep M Llovet; Anna Lok
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

Review 5.  Molecular Pathogenesis of Liver Cancer.

Authors:  Mehmet Ozturk; Tugce Batur; Umut Ekin; Aybike Erdogan; Evin İscan; Umur Keles; Ozden Oz; Cigdem Ozen
Journal:  J Gastrointest Cancer       Date:  2017-09

6.  Structure and expression of a novel frizzled gene isolated from the developing mouse gut.

Authors:  T H Malik; R A Shivdasani
Journal:  Biochem J       Date:  2000-08-01       Impact factor: 3.857

7.  Expression of beta-catenin in hepatocellular carcinoma.

Authors:  Liem Thanh Tien; Masahiro Ito; Mikiko Nakao; Daisuke Niino; Meirmanov Serik; Masahiro Nakashima; Chun-Yang Wen; Hiroshi Yatsuhashi; Hiromi Ishibashi
Journal:  World J Gastroenterol       Date:  2005-04-28       Impact factor: 5.742

8.  Hepatocellular carcinomas in native livers from patients treated with orthotopic liver transplantation: biologic and therapeutic implications.

Authors:  H Kirimlioglu; I Dvorchick; K Ruppert; S Finkelstein; J W Marsh; S Iwatsuki; A Bonham; B Carr; M Nalesnik; G Michalopoulos; T Starzl; J Fung; A Demetris
Journal:  Hepatology       Date:  2001-09       Impact factor: 17.425

9.  An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.

Authors:  George P Kim; Michelle R Mahoney; Daniel Szydlo; Tony S K Mok; Robert Marshke; Kyle Holen; Joel Picus; Michael Boyer; Henry C Pitot; Joseph Rubin; Philip A Philip; Anna Nowak; John J Wright; Charles Erlichman
Journal:  Invest New Drugs       Date:  2010-09-14       Impact factor: 3.850

10.  Evolving therapies in the treatment of hepatocellular carcinoma.

Authors:  Hans Christian Spangenberg; Robert Thimme; Hubert E Blum
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.